Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS G12V T cell engager
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KRAS G12V T cell engager (MA022-2037) is a preclinical-stage, half-life extended bispecific T-cell engager (TCE) being developed by Myrio Therapeutics. Utilizing Myrio's proprietary Retained Display (ReD) platform, the antibody is designed to target the KRAS G12V mutant peptide presented in complex with HLA-A*11:01 on the surface of tumor cells. By simultaneously binding to the CD3 receptor on T cells and the KRAS G12V/HLA-A*11:01 complex on cancer cells, MA022-2037 redirects host T-cell cytolytic activity to selectively eliminate KRAS G12V-mutant tumor cells while sparing wild-type or mismatched tissues. It is currently undergoing IND-enabling studies for the treatment of KRAS G12V-driven solid tumors, including lung, pancreatic, and colon cancers.
- Other names
- KRAS G12V T-cell engagerMutant KRAS G12V
02
Targets
CD3 (T-cell surface glycoprotein CD3)KRAS G12D peptide-HLA complexpMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on KRAS G12V T cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS G12V T cell engager.